Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in ...

If I only have around three years left to live, what's the point in A-levels?" According to bone and soft tissue cancer ...

Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 ...

The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

Synovial sarcoma and MRCLS are rare and often aggressive cancers with limited treatment options. Synovial sarcoma is a soft ...

The ASX rises on positive US inflation news, Xero ticks up 5% and Bitcoin hits US$93k before cooling off a tad.

Ms Deanne Miller (General Counsel, Company Secretary, Chief Op. Officer) ...

INVINCIBLE-3 Study: a Phase 3 open-label, randomized study testing INT230-6 as monotherapy compared to the SOC drugs in second and third line treatment for certain soft tissue sarcoma subtypes. The ...

The ASX rose, led by Xero, while goldies slid. Variscan surged 50pc, Asian stocks dropped, and Bitcoin hit $93k before ...

Brooke began taking OGSIVEO on December 30, 2023, just a month after it was approved by the FDA for adults with progressing ...

Immutep Ltd has unveiled promising Phase II trial results for its novel combination therapy involving eftilagimod alpha, pembrolizumab, and radiotherapy in treating soft tissue sarcoma. The trial ...